Literature DB >> 10702556

Multiple mutations conferring ciprofloxacin resistance in Staphylococcus aureus demonstrate long-term stability in an antibiotic-free environment.

M E Jones1, N M Boenink, J Verhoef, K Köhrer, F J Schmitz.   

Abstract

Two unrelated strains of Staphylococcus aureus, one with a single mutation in grlA, the other with multiple mutations in gyrA, gyrB, grlA, grlB, norA and the norA promoter region, encoding low-level and high-level ciprofloxacin resistance, respectively, were studied. The characterized mutations in these genes were conserved when both strains were passaged for at least 500 generations in an antibiotic-free environment. New, rapidly stabilized mutations and higher MICs were detected for strains passaged in sub-MIC ciprofloxacin concentrations. The seeming irreversibility of quinolone resistance may affect the long-term success of this drug class.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10702556     DOI: 10.1093/jac/45.3.353

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  15 in total

1.  In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus.

Authors:  M Boos; S Mayer; A Fischer; K Köhrer; S Scheuring; P Heisig; J Verhoef; A C Fluit; F J Schmitz
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

2.  Prophylactic treatment of anthrax with antibiotics.

Authors:  C A Hart; N J Beeching
Journal:  BMJ       Date:  2001-11-03

Review 3.  Efflux-mediated resistance to fluoroquinolones in gram-positive bacteria and the mycobacteria.

Authors:  K Poole
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

Review 4.  Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria.

Authors:  Laura J V Piddock
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

5.  Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States.

Authors:  M E Jones; A M Staples; I Critchley; C Thornsberry; P Heinze; H D Engler; D F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

Review 6.  Multidrug efflux pumps in Staphylococcus aureus and their clinical implications.

Authors:  Soojin Jang
Journal:  J Microbiol       Date:  2016-01-05       Impact factor: 3.422

Review 7.  Fluoroquinolones: place in ocular therapy.

Authors:  A Smith; P M Pennefather; S B Kaye; C A Hart
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 8.  Resistance surveillance studies: a multifaceted problem--the fluoroquinolone example.

Authors:  A Dalhoff
Journal:  Infection       Date:  2012-03-30       Impact factor: 3.553

9.  Novel riboswitch ligand analogs as selective inhibitors of guanine-related metabolic pathways.

Authors:  Jérôme Mulhbacher; Eric Brouillette; Marianne Allard; Louis-Charles Fortier; François Malouin; Daniel A Lafontaine
Journal:  PLoS Pathog       Date:  2010-04-22       Impact factor: 6.823

10.  Antimicrobial activities of garenoxacin (BMS 284756) against Asia-Pacific region clinical isolates from the SENTRY program, 1999 to 2001.

Authors:  K J Christiansen; J M Bell; J D Turnidge; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.